Longevity Health Holdings Inc. (XAGE) 10-Year Financial Performance & Capital Metrics

XAGE • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesTissue Repair & Regenerative Medicine

AboutLongevity Health Holdings Inc focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.Show more

Revenue $50K
EBITDA -$5M +5.7%
Net Income -$10M +32.9%
EPS (Diluted) -0.50 +32.4%
Gross Margin 87.37%
EBITDA Margin -9541.79%
Operating Margin -9933.82%
Net Margin -20605.47%
ROE -103.49% -65.8%
ROIC -37.98%
Debt/Equity -
Interest Coverage -101.98 -1638.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM139.43%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM8.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-187.75%

ROCE

10Y Avg-49.97%

5Y Avg-49.97%

3Y Avg-49.97%

Latest-47.51%

Peer Comparison

Tissue Repair & Regenerative Medicine

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
XAGELongevity Health Holdings Inc.	561.25K	0.32	-0.63		-393.63%	-103.49%

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	50.32K
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	242.56K	124.79K	6.36K
COGS % of Revenue	-	-	-	0.13%
Gross Profit+	0	-242.56K	-124.79K	43.96K
Gross Margin %	-	-	-	0.87%
Gross Profit Growth %	-	-	0.49%	1.35%
Operating Expenses+	1.94M	5.27M	5.09M	5.04M
OpEx % of Revenue	-	-	-	100.21%
Selling, General & Admin	863.33K	3.22M	2.6M	3.9M
SG&A % of Revenue	-	-	-	77.6%
Research & Development	982.84K	2.2M	2.5M	1.05M
R&D % of Revenue	-	-	-	20.95%
Other Operating Expenses	94.16K	-148.26K	0	83.49K
Operating Income+	-467.43K	-5.51M	-5.22M	-5M
Operating Margin %	-	-	-	-99.34%
Operating Income Growth %	-	-10.78%	0.05%	0.04%
EBITDA+	-225.31K	-5.27M	-5.09M	-4.8M
EBITDA Margin %	-	-	-	-95.42%
EBITDA Growth %	-	-22.37%	0.03%	0.06%
D&A (Non-Cash Add-back)	242.12K	242.56K	124.79K	197.26K
EBIT	-329.38K	-5.3M	-15.32M	-10.7M
Net Interest Income+	-2.49M	-1.5M	-889.32K	-49.02K
Interest Income	8.09K	2.25M	0	0
Interest Expense	2.5M	3.75M	889.32K	49.02K
Other Income/Expense	138.05K	-3.54M	-10.99M	-5.75M
Pretax Income+	-329.38K	-9.05M	-16.21M	-10.75M
Pretax Margin %	-	-	-	-213.6%
Income Tax+	0	0	0	-97.28K
Effective Tax Rate %	19.67%	1%	0.95%	0.96%
Net Income+	-6.48M	-9.05M	-15.45M	-10.37M
Net Margin %	-	-	-	-206.05%
Net Income Growth %	-	-0.4%	-0.71%	0.33%
Net Income (Continuing)	-329.38K	-9.05M	-16.21M	-10.65M
Discontinued Operations	0	0	760.16K	282.2K
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.01	-0.50	-0.74	-0.50
EPS Growth %	-	-44.87%	-0.48%	0.32%
EPS (Basic)	-0.01	-0.50	-0.74	-0.50
Diluted Shares Outstanding	19.77M	19.77M	20.77M	20.91M
Basic Shares Outstanding	19.77M	19.77M	20.77M	20.91M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	178.7K	605.54K	62.9M	955.55K
Cash & Short-Term Investments	774.19K	128.15K	2.91M	157.14K
Cash Only	774.19K	128.15K	2.91M	157.14K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	204.56K	305.93K
Days Sales Outstanding	-	-	-	2.22K
Inventory	0	0	0	108.7K
Days Inventory Outstanding	-	-	-	6.24K
Other Current Assets	-794.47K	422.32K	59.02M	86.31K
Total Non-Current Assets+	1.38M	1.14M	1.05M	518.43K
Property, Plant & Equipment	1.35M	1.11M	1.02M	498.79K
Fixed Asset Turnover	-	-	-	0.10x
Goodwill	0	0	0	0
Intangible Assets	33.22K	28.7K	24.19K	19.64K
Long-Term Investments	154.45M	156.69M	0	0
Other Non-Current Assets	-154.45M	-156.69M	0	0
Total Assets+	1.56M	1.75M	63.95M	1.47M
Asset Turnover	-	-	-	0.03x
Asset Growth %	-	0.12%	35.57%	-0.98%
Total Current Liabilities+	15.8M	7.3M	38.5M	5.88M
Accounts Payable	871.31K	2.14M	4.42M	4.06M
Days Payables Outstanding	-	3.22K	12.92K	233K
Short-Term Debt	8.6M	2.78M	1.29M	241.16K
Deferred Revenue (Current)	1000K	1000K	0	0
Other Current Liabilities	1.96M	349.26K	31.35M	0
Current Ratio	0.01x	0.08x	1.63x	0.16x
Quick Ratio	0.01x	0.08x	1.63x	0.14x
Cash Conversion Cycle	-	-	-	-224.54K
Total Non-Current Liabilities+	15.33M	32.24M	697.72K	309.94K
Long-Term Debt	922	0	0	0
Capital Lease Obligations	961.91K	827.73K	697.72K	309.94K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	14.37M	31.42M	0	0
Total Liabilities	31.13M	39.54M	39.2M	6.19M
Total Debt+	9.69M	3.74M	2.14M	638.99K
Net Debt	8.91M	3.61M	-776.01K	481.85K
Debt / Equity	-	-	0.09x	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-0.19x	-1.47x	-5.87x	-101.98x
Total Equity+	-29.58M	-37.79M	24.75M	-4.71M
Equity Growth %	-	-0.28%	1.65%	-1.19%
Book Value per Share	-1.50	-1.91	1.19	-0.23
Total Shareholders' Equity	-29.58M	-37.79M	24.75M	-4.71M
Common Stock	36.92K	14.53K	2.31K	2.09K
Retained Earnings	-32.77M	-42.38M	-58.5M	-68.87M
Treasury Stock	0	0	0	0
Accumulated OCI	0	-31.42M	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.18M	-3.81M	-8.35M	-4.39M
Operating CF Margin %	-	-	-	-87.22%
Operating CF Growth %	-	-2.24%	-1.19%	0.47%
Net Income	-6.48M	-9.05M	-15.45M	-11.8M
Depreciation & Amortization	242.12K	242.56K	124.79K	197.26K
Stock-Based Compensation	246.8K	636.37K	667.68K	827.04K
Deferred Taxes	2.52M	-194.59K	0	0
Other Non-Cash Items	1.35M	2.22M	9.73M	5.72M
Working Capital Changes	952.69K	2.34M	-3.42M	669.49K
Change in Receivables	0	0	-204.56K	-101.38K
Change in Inventory	0	0	204.56K	-108.7K
Change in Payables	80.32K	1.06M	-449.87K	-359.14K
Cash from Investing+	-7.27K	-7.16K	-30.47K	-748.8K
Capital Expenditures	-7.27K	-7.16K	-30.47K	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	154.44M	0	0	0
Cash from Financing+	1.2M	3.93M	11.16M	2.38M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	67.82K	125.88K	14.32M	-86.31K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.18M	-3.44M	-8.38M	-4.39M
FCF Margin %	-	-	-	-87.22%
FCF Growth %	-	-1.9%	-1.44%	0.48%
FCF per Share	-0.06	-0.17	-0.40	-0.21
FCF Conversion (FCF/Net Income)	0.18x	0.42x	0.54x	0.42x
Interest Paid	0	0	283.53K	29.47K
Taxes Paid	0	0	750K	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-62.41%	-103.49%
Return on Invested Capital (ROIC)	-	-	-	-37.98%
Gross Margin	-	-	-	87.37%
Net Margin	-	-	-	-20605.47%
Debt / Equity	-	-	0.09x	-
Interest Coverage	-0.19x	-1.47x	-5.87x	-101.98x
FCF Conversion	0.18x	0.42x	0.54x	0.42x

Frequently Asked Questions

Growth & Financials

Longevity Health Holdings Inc. (XAGE) reported $1.5M in revenue for fiscal year 2024.

Longevity Health Holdings Inc. (XAGE) grew revenue by 0.0% over the past year. Growth has been modest.

Longevity Health Holdings Inc. (XAGE) reported a net loss of $5.7M for fiscal year 2024.

Dividend & Returns

Longevity Health Holdings Inc. (XAGE) has a return on equity (ROE) of -103.5%. Negative ROE indicates the company is unprofitable.

Longevity Health Holdings Inc. (XAGE) had negative free cash flow of $3.8M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener